Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Avalo Therapeutics (NASDAQ:AVTX) had its price target upped by research analysts at HC Wainwright from $25.00 to $40.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 197.40% from the company’s current price.

A number of other brokerages have also weighed in on AVTX. Guggenheim assumed coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price on the stock. BTIG Research reissued a “buy” rating and issued a $40.00 price target on shares of Avalo Therapeutics in a research report on Tuesday. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $42.25.

Avalo Therapeutics Stock Performance

AVTX stock opened at $13.45 on Wednesday. The stock’s 50 day simple moving average is $15.57 and its 200 day simple moving average is $15.78. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72. The company has a market cap of $248.96 million, a P/E ratio of -2.35 and a beta of 0.84.

Insider Activity

In related news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the sale, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.25% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new position in Avalo Therapeutics during the 4th quarter worth $1,150,000. XTX Topco Ltd raised its holdings in shares of Avalo Therapeutics by 190.0% in the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after purchasing an additional 26,508 shares during the last quarter. Squadron Capital Management LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at about $2,361,000. SummitTX Capital L.P. purchased a new position in Avalo Therapeutics during the fourth quarter worth about $3,557,000. Finally, Millennium Management LLC boosted its holdings in Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after purchasing an additional 522,548 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.